HIMS Blowout Q3 Leads To Substantial Fair Value Bump
Nov 6, 2024
Hims & Hers delivered yet another blowout result for Q3 - this one the most impressive yet. Revenue growth accelerated to 77%, on the back of both the GLP-1 weight loss drug launch, and the 44% subscriber growth it helped drive. Even ex-GLP sales, revenues soared 40%. The weight loss drug launch has also supercharged the Hers brand, giving the company yet another growth avenue. The stock is up over 150% since we added it a year ago, but now looks like as good a time as ever to add. The fair value gets a substantial bump from $21 to $28.
Follow @GreenDotStocks
Information contained on this website represents only the opinions of the author and should not be used as the sole basis for investing decisions. By using this site, you agree to all statements in the Site Policy.
Watch List
| S | 9.41% |
| CRWD | 73.34% |
| SEMR | -15.86% |
| SNOW | 15.48% |
| TSM | -1.89% |
vs. Fair Value Estimates
Buy List
| GOOG | -33.69% |
| NYAX | -61.69% |
| ASR | -31.25% |
| PAYC | -28.54% |
| HRMY | -49.59% |
| YOU | -45.59% |
| MELI | -30.27% |
| ADBE | -30.99% |
vs. Fair Value Estimates
Hold List
| MSFT | -21.19% |
| ODD | -23.90% |
| FLYW | 4.57% |
| CELH | -15.59% |
| TOST | 31.86% |
| CPNG | -2.38% |
| HIMS | -6.43% |
| MNDY | 15.47% |
| GLBE | 16.55% |
| ZS | 18.59% |
| V | -11.99% |
| ADSK | 11.66% |
| NOW | 50.93% |
| ABNB | -19.63% |
| FTNT | 4.51% |
| TEAM | 14.85% |
vs. Fair Value Estimates